Linear
Clinical
Research
Limited,
the
clinical
trials
arm
of
the
Harry
Perkins
Institute
of
Medical
Research,
is
delighted
to
announce
the
appointment
of
Dr
Michael
Winlo
as
its
new
CEO.
Dr Winlo is originally from Perth and earned his bachelor of medicine and surgery with honours from the University of Western Australia in 2005.
Most notably, Dr Winlo has spent the last six years between Silicon Valley and New York growing the health practice of the highly regarded data analysis firm Palantir Technologies.
Throughout his career Dr Winlo has acquired strong skills in global business development, medical technology investment, health data analysis and project management. He is looking forward to joining Linear.
“Linear is a world--class organisation with a compelling mission to improve patient access to new treatments and accelerate clinical research. I’m thrilled to return home and apply the unique experiences I attained overseas to serve as CEO,” Dr Winlo said.
In announcing Dr Winlo’s appointment, Linear Chairman Professor Peter Leedman said: “we believe Michael has the energy and talent to build on our successes and ensure Linear remains a global leader in early stage clinical trials.”
Dr Winlo earned an MBA from the Stanford Graduate School of Business and holds multiple patents in health data analysis. He begins his new role as CEO on Monday, 4 April 2016.
For more information www.perkins.org.au For further information, interviews and images, please contact: Alicia Murray--Jones Communications Officer | Harry Perkins Institute of Medical Research M 0417 254 242 | P +61 8 6151 0726 | E alicia.murray--jones@perkins.uwa.edu.au
Dr Winlo is originally from Perth and earned his bachelor of medicine and surgery with honours from the University of Western Australia in 2005.
Most notably, Dr Winlo has spent the last six years between Silicon Valley and New York growing the health practice of the highly regarded data analysis firm Palantir Technologies.
Throughout his career Dr Winlo has acquired strong skills in global business development, medical technology investment, health data analysis and project management. He is looking forward to joining Linear.
“Linear is a world--class organisation with a compelling mission to improve patient access to new treatments and accelerate clinical research. I’m thrilled to return home and apply the unique experiences I attained overseas to serve as CEO,” Dr Winlo said.
In announcing Dr Winlo’s appointment, Linear Chairman Professor Peter Leedman said: “we believe Michael has the energy and talent to build on our successes and ensure Linear remains a global leader in early stage clinical trials.”
Dr Winlo earned an MBA from the Stanford Graduate School of Business and holds multiple patents in health data analysis. He begins his new role as CEO on Monday, 4 April 2016.
For more information www.perkins.org.au For further information, interviews and images, please contact: Alicia Murray--Jones Communications Officer | Harry Perkins Institute of Medical Research M 0417 254 242 | P +61 8 6151 0726 | E alicia.murray--jones@perkins.uwa.edu.au
